These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31335544)

  • 1. Mission Impossible or Mission Futile?: Estimating Penetrance for Malignant Hyperthermia.
    Shaw MA; Hopkins PM
    Anesthesiology; 2019 Nov; 131(5):957-959. PubMed ID: 31335544
    [No Abstract]   [Full Text] [Related]  

  • 2. Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia.
    Urwyler A; Halsall PJ; Mueller C; Robinson R
    Acta Anaesthesiol Scand; 2003 Apr; 47(4):492; author reply 493. PubMed ID: 12694155
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.
    Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM
    J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopathic changes in malignant hyperthermia-susceptible patients.
    Rosenberg H
    Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
    [No Abstract]   [Full Text] [Related]  

  • 5. Perinatal diagnosis of malignant hyperthermia susceptibility.
    Girard T; Jöhr M; Schaefer C; Urwyler A
    Anesthesiology; 2006 Jun; 104(6):1353-4. PubMed ID: 16732128
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces?
    Mathews KD; Moore SA
    Arch Neurol; 2004 Jan; 61(1):27-9. PubMed ID: 14732615
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
    Beam TA; Loudermilk EF; Kisor DF
    Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant hyperthermia.
    Bouchama A; Hussain S
    Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignant hyperthermia and apparent heat stroke.
    Tobin JR; Jason DR; Challa VR; Nelson TE; Sambuughin N
    JAMA; 2001 Jul; 286(2):168-9. PubMed ID: 11448278
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in patients with malignant hyperthermia.
    Rueffert H; Kraus H; Olthoff D; Deutrich C; Froster UG
    Hum Mutat; 2001 Mar; 17(3):238. PubMed ID: 11241852
    [No Abstract]   [Full Text] [Related]  

  • 12. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
    MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
    J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
    Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
    Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of malignant hyperthermia.
    Brandom BW
    ScientificWorldJournal; 2006 Dec; 6():1722-30. PubMed ID: 17195870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population.
    Kraeva N; Riazi S; Loke J; Frodis W; Crossan ML; Nolan K; Kraev A; Maclennan DH
    Can J Anaesth; 2011 Jun; 58(6):504-13. PubMed ID: 21455645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetic mystery in malignant hyperthermia 'solved'?
    Schiemann AH; Bjorksten AR; Gillies RL; Hockey BM; Ball C; Pollock N; Bulger T; Stowell KM
    Br J Anaesth; 2018 Sep; 121(3):681-682. PubMed ID: 30115273
    [No Abstract]   [Full Text] [Related]  

  • 18. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.
    Vladutiu G
    Arthritis Rheum; 2007 Feb; 57(1):186-7; author reply 187-8. PubMed ID: 17266123
    [No Abstract]   [Full Text] [Related]  

  • 19. Duchenne muscular dystrophy and malignant hyperthermia: a genetic study of the ryanodine receptor in 47 patients.
    Rohde D; Schmitt HJ; Winterpacht A; Münster T
    Eur J Anaesthesiol; 2014 Jun; 31(6):341-2. PubMed ID: 24557023
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families.
    Sambuughin N; Nelson TE; Jankovic J; Xin C; Meissner G; Mullakandov M; Ji J; Rosenberg H; Sivakumar K; Goldfarb LG
    Neuromuscul Disord; 2001 Sep; 11(6-7):530-7. PubMed ID: 11525881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.